56442-17-2

Basic information

• Product Name: 4-(4-FLUOROBENZYLOXY)BENZALDEHYDE
• Synonyms: ART-CHEM-BB B014207;ASISCHEM N47999;4-(4-FLUOROBENZYLOXY)BENZALDEHYDE;AKOS B014207;TIMTEC-BB SBB002110;4-(4-Fluorobenzyloxy)benzaldehyde 97%;4-(4-Fluorobenzyloxy)benzaldehyde97%;4-(4-Fluorobenzyloxy)benzaldehyde,98%
• CAS NO: 56442-17-2
• Molecular Formula: C₁₄H₁₁FO₂
• Molecular Weight: 230.23
• Mol File: 56442-17-2.mol
• Article Data: 20

Chemical Properties

• Melting Point: 96-100 °C
• Boiling Point: 370.2 °C at 760 mmHg
• Flash Point: 171.7 °C
• Appearance: Beige/Powder
• Density: 1.29g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Inert atmosphere,Room Temperature
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-(4-FLUOROBENZYLOXY)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FLUOROBENZYLOXY)BENZALDEHYDE(56442-17-2)
• EPA Substance Registry System: 4-(4-FLUOROBENZYLOXY)BENZALDEHYDE(56442-17-2)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 56442-17-2(Hazardous Substances Data)

Usage

Chemical Properties

beige powder

InChI:InChI=1/C14H11FO2/c15-13-5-1-12(2-6-13)10-17-14-7-3-11(9-16)4-8-14/h1-9H,10H2

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 459-46-1 4-Fluorobenzyl bromide 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 223650-14-4 α-[4-(4-fluorobenzyloxy)phenyl]-N-tert-butylnitrone 
• 1129693-29-3 (S)-N-(4-(4-fluorobenzyloxy)benzyl)-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-amine 
• 247566-73-0 5-(4-(4-fluorobenzyloxy)benzylidene)-2-thioxothiazolidin-4-one 
• 1186634-04-7 (4-(5-(1-(4-(4-fluorobenzyloxy)phenyl)methylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)acetic acid methyl ester 
• 1055977-81-5 (Z)-5-[4-(4-fluorobenzyloxy)benzylidene]thiazolidine-2,4-dione 
• 1399258-99-1 N-[4-(4-fluoro-benzyloxy)-benzyl]-hydroxylamine 
• 432529-50-5 4-(4-fluorobenzyloxy)benzaldehyde oxime 
• 1399259-05-2 (4aS,4bR,5S,6aS,6bR,9aS,10aS,10bS,12S)-4b,12-difluoro-8-[4-(4-fluoro-benzyloxy)-benzyl]-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4a,4b,5,6,6a,6b,8,9,9a,10,10a,10b,11,12-tetradecahydro-7-oxa-8-aza-pentaleno[2,1-a]phenanthren-2-one 
• 1399259-07-4 (4aS,4bR,5S,6aS,6bR,9aS,10aS,10bS,12S)-4b,12-difluoro-8-[4-(4-fluoro-benzyloxy)-benzyl]-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,8,9,9a,10,10a,10b,11,12-tetradecahydro-7-oxa-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid 
• 1399259-09-6 (4aS,4bR,5S,6aS,6bR,9aS,10aS,10bS,12S)-8-((4-fluoro-benzyloxy)-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,8,9,9a,10,10a,10b,11,12-tetradecahydro-7-oxa-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester 
• 1414806-55-5 (S,E)-2-(5-(4-(4-fluorobenzyloxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid 
• 1431881-22-9 ehyl 2-(4-((4-fluorobenzyl)oxy)phenyl)thieno[3',2':3,4]-benzo-[1,2-d]thiazole-7-carboxylate 

Relevant articles and documents

Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity

Encouraged by our earlier discovery of N1-selective inhibitors, the 150-cavity of influenza virus neuraminidases (NAs) could be further exploited to yield more potent oseltamivir derivatives. Herein, we report the design, synthesis and biological evaluation of a series of novel oseltamivir derivatives via the structural modifications at C5–NH2 of oseltamivir targeting 150-cavity. Among them, compound 5c bearing 4-(3-methoxybenzyloxy)benzyl group exhibited the most potent activity, which was lower or modestly improved activities than oseltamivir carboxylate (OSC) against N1 (H1N1), N1 (H5N1) and N1 (H5N1–H274Y). Specifically, there was 30-fold loss of activity against the wild-type strain H1N1. However, 5c displayed 4.85-fold more potent activity than OSC against H5N1–H274Y NA. Also, 5c demonstrated low cytotoxicity in vitro and no acute toxicity in mice. Molecular docking studies provided insights into the high potency of 5c against N1 and N1–H274Y mutant NAs. Besides, the in silico prediction of physicochemical properties and CYP enzymatic inhibitory ability of representative compounds were conducted to evaluate their drug-like properties.

Synthesis and biological evaluation of novel 4-oxo-5-cyano thiouracil derivatives as SecA inhibitors

The continuous emergence of drug-resistant strains of bacteria poses an urgent risk to human health and dictates the need for new antimicrobials. Along this line, we have been working on developing inhibitors of SecA, a key component of the bacterial Sec-dependent secretion machinery. Herein, we describe the synthesis and antimicrobial evaluation of 6-oxo-1,6-dihydropyrimidine- 5-carbonitrile derivatives as potential SecA inhibitors.

Novel cinnamic acid–tryptamine hybrids as potent butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study

A novel series of cinnamic acid–tryptamine hybrids was designed, synthesized, and evaluated as cholinesterase inhibitors. Anticholinesterase assays showed that all of the synthesized compounds displayed a clearly selective inhibition of butyrylcholinesterase (BChE), but only a moderate inhibitory effect toward acetylcholinesterase (AChE) was detected. Among these cinnamic acid–tryptamine hybrids, compound 7d was found to be the most potent inhibitor of BChE with an IC50 value of 0.55 ± 0.04 μM. This compound showed a 14-fold higher inhibitory potency than the standard drug donepezil (IC50 = 7.79 ± 0.81 μM) and inhibited BChE through a mixed-type inhibition mode. Moreover, a docking study revealed that compound 7d binds to both the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of BChE. Also, compound 7d was evaluated against β-secretase, which exhibited low activity (inhibition percentage: 38%).